Arkansas
Requires Coverage of Comprehensive Biomarker Testing
Only for some plans
Highlighted Disparity
Cancer data are not available for Arkansas due to the impact of COVID-19 on cancer surveillance in 2021.
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases is 68.2 and significantly higher than the national rate of 53.6.
- Arkansas ranks 46th among all states, placing it in the below average tier.
- Over the last five years, the rate of new cases improved by 9%.
5-Year Survival Rate:
- The percent of people alive five years after being diagnosed with lung cancer (the survival rate) in Arkansas is 22.6%, which is significantly lower than the national rate of 28.4%.
- It ranks 45th among the 47 states with survival data, placing it in the bottom tier.
- Over the last five years, the survival rate in Arkansas improved by 15%.
Early Diagnosis:
- The early diagnosis rate is not available for Arkansas due to the impact of COVID-19 on cancer surveillance in 2021.
Lung Cancer Treatment
Surgical Treatment:
- Nationally, 20.7% of cases undergo surgery as part of the first course of treatment. Data on surgery as part of the first course of treatment is not available for Arkansas due to the impact of COVID-19 on cancer surveillance in 2021.
- Over the last five years, the percent of cases undergoing surgery in Arkansas declined by 100%.
Biomarker Coverage:
- Arkansas required some insurance plans to cover comprehensive biomarker testing, including for lung cancer, as of September 2024.
Lack of Treatment:
- Nationally, 20.9% of cases receive no treatment. Data on surgery as part of the first course of treatment is not available for Arkansas due to the impact of COVID-19 on cancer surveillance in 2021.
- Over the last five years, the percent of cases receiving no treatment in Arkansas improved by 100%.
Screening
Screening for High Risk:
- In Arkansas, 14.3% of those at high risk were screened, which was not significantly different than the national rate of 16.0%.
- It ranks 33rd among all states, placing it in the below average tier.
Prevention
Tobacco Use:
- The smoking rate in Arkandas is 18.7% and significantly higher than the national rate of 12.9%.
- It ranks 50th among all states, placing it in the bottom tier.
Radon:
- In Arkansas, 20.1% of radon tests results were at or above the action level recommended by EPA.
- It ranks 20th among all states, placing it in the average tier.
Racial & Ethnic Disparities
Black individuals:
- The rate of new lung cancer cases is 65.7 per 100,000 population among Black individuals in Arkansas, significantly higher than the rate of 55.1 among Black individuals nationally, and not significantly different than the rate of 69.7 among white individuals in Arkansas.
- The five-year survival rate is 19.2% among Black individuals in Arkansas, significantly lower than the rate of 25.5% among Black individuals nationally, and significantly lower than the rate of 23.1% among white individuals in Arkansas.
- Lung cancer rates are not available for Arkansas due to the impact of COVID-19 on cancer surveillance in 2021.
Latino individuals:
- The rate of new lung cancer cases is 41.0 per 100,000 population among Latino individuals in Arkansas, significantly higher than the rate of 28.1 among Latino individuals nationally, and significantly lower than the rate of 69.7 among white individuals in Arkansas.
- State-level survival rates are not available for Latino individuals at this time. Nationally, the five-year survival rate among Latino individuals is 22.7%, not significantly different than the rate of 25.0% among white individuals.
- Lung cancer rates are not available for Arkansas due to the impact of COVID-19 on cancer surveillance in 2021.
Asian Americans or Pacific Islanders:
- The rate of new lung cancer cases is 34.6 per 100,000 population among Asian or Pacific Islanders individuals in Arkansas, not significantly different than the rate of 32.5 among Asian or Pacific Islanders individuals nationally, and significantly lower than the rate of 69.7 among white individuals in Arkansas.
- State-level survival rates are not available for Asian or Pacific Islander individuals at this time. Nationally, the five-year survival rate among Asian or Pacific Islander individuals is 28.6% and significantly higher than the rate of 25.0% among white individuals.
- Lung cancer rates are not available for Arkansas due to the impact of COVID-19 on cancer surveillance in 2021.
Indigenous Peoples:
- The rate of new lung cancer cases is 60.4 per 100,000 population among Indigenous Peoples (American Indians/Alaska Natives) in Arkansas, significantly higher than the rate of 39.9 among Indigenous Peoples nationally, and not significantly different than the rate of 69.7 among white individuals in Arkansas.
- State-level survival rates are not available for Indigenous Peoples at this time. Nationally, the five-year survival rate among Indigenous Peoples is 22.3% and not significantly different than the rate of 25.0% among white individuals.
- Lung cancer rates are not available for Arkansas due to the impact of COVID-19 on cancer surveillance in 2021.
Summary
Early diagnosis data is not available for Arkansas. When this rate increases, we can anticipate that the surgery rate would increase, as surgery is often the recommended treatment for those diagnosed at an earlier stage. In addition, when cases are found earlier, we would expect the five-year survival rate to increase.
Arkansas required some insurance plans to cover comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
Page last updated: November 12, 2024